Marine pharmacology in 2000: Antitumor and cytotoxic compounds
- 12 March 2003
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 105 (3) , 291-299
- https://doi.org/10.1002/ijc.11080
Abstract
During 2000, marine antitumor pharmacology research aimed at the discovery of novel antitumor agents was published in 85 peer‐reviewed articles. The purpose of this article is to present a structured review of the antitumor and cytotoxic properties of 143 marine natural products, many of them novel compounds that belong to diverse structural classes, including polyketides, terpenes, steroids and peptides. The organisms yielding these bioactive compounds comprised a taxonomically diverse group of marine invertebrate animals, algae, fungi and bacteria. Antitumor pharmacological studies were conducted with 19 marine natural products in a number of experimental and clinical models that defined or further characterized their mechanisms of action. Potentially promising in vitro cytotoxicity data generated with murine and human tumor cell lines were reported for 124 novel marine chemicals with as yet undetermined mechanisms of action. Noteworthy is the fact that marine anticancer research clearly remains a multinational effort, involving researchers from Austria, Australia, Brazil, Canada, England, France, Germany, Greece, Indonesia, Italy, Japan, New Zealand, Russia, Spain, South Korea, Switzerland, Taiwan, the Netherlands and the United States. Finally, this 2000 overview of the marine pharmacology literature highlights the fact that the discovery of novel marine antitumor agents continued at the same high level of research activity as during 1998 and 1999.Keywords
This publication has 77 references indexed in Scilit:
- Interaction of the Antitumor Compound Cryptophycin-52 with TubulinBiochemistry, 2000
- Inhibition of Protein Synthesis by Didemnins: Cell Potency and SARJournal of Medicinal Chemistry, 2000
- Antitumor activity of cryptophycins: effect of infusion time and combination studiesCancer Chemotherapy and Pharmacology, 2000
- A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinomaCancer, 2000
- Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activationProceedings of the National Academy of Sciences, 2000
- Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743Proceedings of the National Academy of Sciences, 2000
- Phase II Trial of Didemnin B in Previously Treated Non-Hodgkin’s LymphomaAmerican Journal of Clinical Oncology, 2000
- Induction of apoptosis and inhibition of DNA topoisomerase-I in K-562 cells by a marine microalgal polysaccharideLife Sciences, 2000
- Different microtubule network alterations induced by pachymatismin, a new marine glycoprotein, on two prostatic cell linesCancer Chemotherapy and Pharmacology, 2000
- Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanismInternational Journal of Radiation Biology, 2000